The Differential Diagnosis of an Elevated Amino-Terminal Pro-B-Type Natriuretic Peptide Level

American Journal of Cardiology

Volumn 101, Issue 3 SUPPL., 2008, Pages

  Baggish, Aaron L ^a   van Kimmenade, Roland R J ^a,b   Januzzi Jr , James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER;

ANEMIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; COR PULMONALE; CRITICAL ILLNESS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; HAZARD RATIO; HEART ATRIUM ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART RHYTHM; HUMAN; MITRAL VALVE STENOSIS; MORTALITY; MYOCARDIAL DISEASE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RISK FACTOR; STATISTICAL SIGNIFICANCE; VALVULAR HEART DISEASE;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX;

EID: 38649138526     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.019     Document Type: Article

References (64)

1. Martinez-Rumayor A., Richards A.M., Burnett J.C., and Januzzi Jr. J.L. Biology of the natriuretic peptides. Am J Cardiol 101 (2008) 3A-8A
2. Araujo A.Q., Arteaga E., Ianni B.M., Buck P.C., Rabello R., and Mady C. Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 96 (2005) 1563-1567
3. Arteaga E., Araujo A.Q., Buck P., Ianni B.M., Rabello R., and Mady C. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 150 (2005) 1228-1232
4. Brito D., Matias J.S., Sargento L., Cabral M.J., and Madeira H.C. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy. Rev Port Cardiol 23 (2004) 1557-1582
5. Ha J.W., Cho J.R., Kim J.M., Ahn J.A., Choi E.Y., Kang S.M., Rim S.J., and Chung N. Tissue Doppler-derived indices predict exercise capacity in patients with apical hypertrophic cardiomyopathy. Chest 128 (2005) 3428-3433
6. Kim S.W., Park S.W., Lim S.H., Kwon S.U., Choi Y.J., Park M.K., Lee S.C., Lee S.H., Park J.E., and Jeon E.S. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction. Clin Cardiol 29 (2006) 155-160
7. Mutlu B., Bayrak F., Kahveci G., Degertekin M., Eroglu E., and Basaran Y. Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. Am J Cardiol 98 (2006) 1504-1506
8. Thaman R., Esteban M.T., Barnes S., Gimeno J.R., Mist B., Murphy R., Collinson P.O., McKenna W.J., and Elliott P.M. Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 98 (2006) 515-519
9. Palladini G., Campana C., Klersy C., Balduini A., Vadacca G., Perfetti V., Perlini S., Obici L., Ascari E., d'Eril G.M., Moratti R., and Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107 (2003) 2440-2445
10. Palladini G., Lavatelli F., Russo P., Perlini S., Perfetti V., Bosoni T., Obici L., Bradwell A.R., D'Eril G.M., Fogari R., Moratti R., and Merlini G. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107 (2006) 3854-3858
11. Nef H.M., Möllmann H., Troidl C., Weber M., Hamm C., and Elsässer A. Tako-Tsubo cardiomyopathy: NT-proBNP as a reliable parameter of a favourable prognosis?. [letter]. Int J Cardiol (2007) (in press)
12. Matsumori A., Shimada T., Chapman N.M., Tracy S.M., and Mason J.W. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail 12 (2006) 293-298
13. Horacek J.M., Pudil R., Tichy M., Jebavy L., Strasova A., Praus R., Zak P., and Maly J. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma 52 (2005) 430-434
14. Knobloch K., Tepe J., Lichtinghagen R., Luck H.J., and Vogt P.M. Monitoring of cardiotoxicity during immunotherapy with Herceptin using simultaneous continuous wave Doppler depending on N-terminal pro-brain natriuretic peptide. Clin Med 7 (2007) 88-89 author reply 89
15. Kouloubinis A., Kaklamanis L., Ziras N., Sofroniadou S., Makaritsis K., Adamopoulos S., Revela I., Athanasiou A., Mavroudis D., and Georgoulias V. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. Int J Cardiol 122 (2007) 195-201
16. Kuittinen T., Husso-Saastamoinen M., Sipola P., Vuolteenaho O., Ala-Kopsala M., Nousiainen T., Jantunen E., and Hartikainen J. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 36 (2005) 1077-1082
17. Kuittinen T., Jantunen E., Vanninen E., Mussalo H., Vuolteenaho O., Ala-Kopsala M., Nousiainen T., and Hartikainen J. Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Eur J Haematol 77 (2006) 120-127
18. Sandri M.T., Salvatici M., Cardinale D., Zorzino L., Passerini R., Lentati P., Leon M., Civelli M., Martinelli G., and Cipolla C.M. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. Clin Chem 51 (2005) 1405-1410
19. Germanakis I., Kalmanti M., Parthenakis F., Nikitovic D., Stiakaki E., Patrianakos A., and Vardas P.E. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol 108 (2006) 212-215
20. Gerber I.L., Legget M.E., West T.M., Richards A.M., and Stewart R.A. Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 95 (2005) 898-901
21. Gerber I.L., Stewart R.A., Legget M.E., West T.M., French R.L., Sutton T.M., Yandle T.G., French J.K., Richards A.M., and White H.D. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 107 (2003) 1884-1890
22. Kupari M., Turto H., Lommi J., Makijarvi M., and Parikka H. Transcardiac gradients of N-terminal B-type natriuretic peptide in aortic valve stenosis. Eur J Heart Fail 7 (2005) 809-814
23. Weber M., Arnold R., Rau M., Brandt R., Berkovitsch A., Mitrovic V., and Hamm C. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol 94 (2004) 740-745
24. Nessmith M.G., Fukuta H., Brucks S., and Little W.C. Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol 96 (2005) 1445-1448
25. Weber M., Arnold R., Rau M., Elsaesser A., Brandt R., Mitrovic V., and Hamm C. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 26 (2005) 1023-1030
26. Gerber I.L., Stewart R.A., French J.K., Legget M.E., Greaves S.C., West T.M., Kerr A.J., Richards A.M., and White H.D. Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation. Am J Cardiol 92 (2003) 755-758
27. Eimer M.J., Ekery D.L., Rigolin V.H., Bonow R.O., Carnethon M.R., and Cotts W.G. Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function. Am J Cardiol 94 (2004) 676-678
28. Ozkan M., Baysan O., Erinc K., Koz C., Yokusoglu M., Uzun M., Sag C., Genc C., Karaeren H., and Isik E. Brain natriuretic peptide and the severity of aortic regurgitation: is there any correlation?. J Int Med Res 33 (2005) 454-459
29. Arat-Ozkan A., Kaya A., Yigit Z., Balci H., Okcun B., Yazicioglu N., and Kucukoglu S. Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. Echocardiography 22 (2005) 473-478
30. Brookes C.I., Kemp M.W., Hooper J., Oldershaw P.J., and Moat N.E. Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. J Heart Valve Dis 6 (1997) 608-612
31. Mayer S.A., de Lemos J.A., Murphy S.A., Brooks S., Roberts B.J., and Grayburn P.A. Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation. Am J Cardiol 93 (2004) 1002-1006
32. Sutton T.M., Stewart R.A.H., Gerber I.L., West T.M., Richards A.M., Yandle T.G., and Kerr A.J. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 41 (2003) 2280-2287
33. Sutton T.M., Stewart R.A., Gerber I.L., West T.M., Richards A.M., Yandle T.G., and Kerr A.J. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 41 (2003) 2280-2287
34. Detaint D., Messika-Zeitoun D., Avierinos J.F., Scott C., Chen H., Burnett Jr. J.C., and Enriquez-Sarano M. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 111 (2005) 2391-2397
35. Morello A., Lloyd-Jones D.M., Chae C.U., van Kimmenade R.R., Chen A.C., Baggish A.L., O'Donoghue M., Lee-Lewandrowski E., and Januzzi Jr. J.L. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J 153 (2007) 90-97
36. Shelton R.J., Clark A.L., Goode K., Rigby A.S., and Cleland J.G. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. Eur Heart J 27 (2006) 2353-2361
37. Shin D.I., Jaekel K., Schley P., Sause A., Muller M., Fueth R., Scheffold T., Guelker H., and Horlitz M. Plasma levels of NT-pro-BNP in patients with atrial fibrillation before and after electrical cardioversion. Z Kardiol 94 (2005) 795-800
38. Tuinenburg A.E., Brundel B.J., Van Gelder I.C., Henning R.H., Van den Berg M.P., Driessen C., Grandjean J.G., Van Gilst W.H., and Crijns H.J. Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol 10 (1999) 827-835
39. Ellinor P.T., Low A.F., Patton K.K., Shea M.A., and Macrae C.A. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol 45 (2005) 82-86
40. Rienstra M., Van Gelder I.C., Van den Berg M.P., Boomsma F., and Van Veldhuisen D.J. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. Europace 8 (2006) 482-487
41. Januzzi J.L., van Kimmenade R., Lainchbury J., Bayes-Genis A., Ordonez-Llanos J., Santalo-Bel M., Pinto Y.M., and Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27 (2006) 330-337
42. Nybo M., Kristensen S.R., Mickley H., and Jensen J.K. The influence of anaemia on stroke prognosis and its relation to N-terminal pro-brain natriuretic peptide. Eur J Neurol 14 (2007) 477-482
43. Willis M.S., Lee E.S., and Grenache D.G. Effect of anemia on plasma concentrations of NT-proBNP. Clin Chim Acta 358 (2005) 175-181
44. Baggish A.L., van Kimmenade R., Bayes-Genis A., Davis M., Lainchbury J.G., Frampton C., Pinto Y., Richards M.A., and Januzzi J.L. Hemoglobin and N-terminal pro-brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure: results from the International Collaborative of NT-proBNP (ICON) Study. Clin Chim Acta 381 (2007) 145-150
45. Machado R.F., Anthi A., Steinberg M.H., Bonds D., Sachdev V., Kato G.J., Taveira-DaSilva A.M., Ballas S.K., Blackwelder W., Xu X., et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 296 (2006) 310-318
46. Chua G., and Kang-Hoe L. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit Care 8 (2004) R248-R250
47. Januzzi J.L., Morss A., Tung R., Pino R., Fifer M.A., Thompson B.T., and Lee-Lewandrowski E. Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. [research]. Crit Care 10 (2006) R37
48. Almog Y., Novack V., Megralishvili R., Kobal S., Barski L., King D., and Zahger D. Plasma level of N terminal pro-brain natriuretic peptide as a prognostic marker in critically ill patients. Anesth Analg 102 (2006) 1809-1815
49. Roch A., Allardet-Servent J., Michelet P., Oddoze C., Forel J.M., Barrau K., Loundou A., Perrin G., Auffray J.P., Portugal H., and Papazian L. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 33 (2005) 1001-1007
50. Rudiger A., Gasser S., Fischler M., Hornemann T., von Eckardstein A., and Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 34 (2006) 2140-2144
51. Brueckmann M., Huhle G., Lang S., Haase K.K., Bertsch T., Weiss C., Kaden J.J., Putensen C., Borggrefe M., and Hoffmann U. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 112 (2005) 527-534
52. Giannakoulas G., Hatzitolios A., Karvounis H., Koliakos G., Charitandi A., Dimitroulas T., Savopoulos C., Tsirogianni E., and Louridas G. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology 56 (2005) 723-730
53. Iltumur K., Karabulut A., Yokus B., Yavuzkir M., Taskesen T., and Toprak N. N-terminal proBNP plasma levels correlate with severity of mitral stenosis. J Heart Valve Dis 14 (2005) 735-741
54. Jensen J.K., Mickley H., Bak S., Korsholm L., and Kristensen S.R. Serial measurements of N-terminal pro-brain natriuretic peptide after acute ischemic stroke. Cerebrovasc Dis 22 (2006) 439-444
55. Yip H.K., Sun C.K., Chang L.T., Chen M.C., and Liou C.W. Time course and prognostic value of plasma levels of N-terminal pro-brain natriuretic peptide in patients after ischemic stroke. Circ J 70 (2006) 447-452
56. Kirchhoff C., Stegmaier J., Bogner V., Buhmann S., Mussack T., Kreimeier U., Mutschler W., and Biberthaler P. Intrathecal and systemic concentration of NT-proBNP in patients with severe traumatic brain injury. J Neurotrauma 23 (2006) 943-949
57. Goetze J.P., Videbaek R., Boesgaard S., Aldershvile J., Rehfeld J.F., and Carlsen J. Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease. J Heart Lung Transplant 23 (2004) 80-87
58. van Kimmenade R.R.J., Pinto Y.M., Bayes-Genis A., Lainchbury J.G., Richards A.M., and Januzzi Jr. J.L. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol 98 (2006) 386-390
59. Pruszczyk P., Kostrubiec M., Bochowicz A., Styczynski G., Szulc M., Kurzyna M., Fijalkowska A., Kuch-Wocial A., Chlewicka I., and Torbicki A. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 22 (2003) 649-653
60. Pruszczyk P. N-terminal pro-brain natriuretic peptide as an indicator of right ventricular dysfunction. J Card Fail 11 suppl (2005) S65-S69
61. Kucher N., Printzen G., Doernhoefer T., Windecker S., Meier B., and Hess O.M. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 107 (2003) 1576-1578
62. Pepperell J., Stradling J., and Davies R. Brain natriuretic peptide is unchanged after 4 weeks of continuous positive airway pressure therapy. J Sleep Res 15 (2006) 463-464
63. Fijalkowska A., Kurzyna M., Torbicki A., Szewczyk G., Florczyk M., Pruszczyk P., and Szturmowicz M. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129 (2006) 1313-1321
64. Allanore Y., Borderie D., Meune C., Cabanes L., Weber S., Ekindjian O.G., and Kahan A. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 48 (2003) 3503-3508